Acute myelogenous leukemia in adolescents and young adults Journal Articles

Overview
Research
Identity
Additional Document Info
View All

abstract

AbstractThe incidence of acute myelogenous leukemia (AML) increases progressively with age. Favorable genetic mutations are most prevalent in children, and unfavorable profiles increase proportionately in adolescents and young adults (AYA) and into later adulthood. Survival rates of AYA have improved over recent decades to 50–60%, but their accrual to clinical trials remains poor. In contrast to AYA with acute lymphoblastic leukemia, the prognostic benefit for AYA with AML enrolled in pediatric compared with adult trials is minor and only seen when different protocols are used. The distinctive needs of AYA, including intensive psychological services, call for their treatment within specialized centers that offer complex supportive care.

authors

Creutzig, Ursula
Kutny, Matthew A
Barr, Ronald Duncan
Schlenk, Richard F
Ribeiro, Raul C

status

published

publication date

September 2018

has subject area

1103 Clinical Sciences (FoR)
1112 Oncology and Carcinogenesis (FoR)
1114 Paediatrics and Reproductive Medicine (FoR)
Abnormal Karyotype (MeSH)
Adolescent (MeSH)
Adult (MeSH)
Age of Onset (MeSH)
Antineoplastic Combined Chemotherapy Protocols (MeSH)
Cell Differentiation (MeSH)
Child (MeSH)
Child, Preschool (MeSH)
Clinical Trials as Topic (MeSH)
Europe (MeSH)
Female (MeSH)
Hematopoietic Stem Cell Transplantation (MeSH)
Humans (MeSH)
Incidence (MeSH)
Infant (MeSH)
Infertility (MeSH)
Leukemia, Myeloid, Acute (MeSH)
Male (MeSH)
Middle Aged (MeSH)
Multicenter Studies as Topic (MeSH)
Neoplasms, Second Primary (MeSH)
Oncology & Carcinogenesis (Science Metrix)
Patient Selection (MeSH)
Prognosis (MeSH)
Survival Analysis (MeSH)
United States (MeSH)
Young Adult (MeSH)

published in

Pediatric Blood and Cancer Journal